Compounded Semaglutide and Tirzepatide: What 'Compounded' Actually Means and the Real Sourcing Risks

Compounded semaglutide and tirzepatide became widely available for one specific legal reason: FDA drug-shortage rules allow licensed compounding pharmacies to produce a version of an otherwise-patented drug when the brand-name product is officially listed as being in shortage. That exception, not equivalence to the branded product, is the entire basis for compounded GLP-1s existing at scale.

The Shortage Exception, and Why It's Narrowing

Under normal circumstances, compounding a copy of a patented, commercially available drug is not allowed. The shortage exception temporarily lifts that restriction so patients aren't left without treatment options during a supply gap. As manufacturers have scaled production and the FDA has moved semaglutide and, later, tirzepatide off the official shortage list at various points, the legal basis for mass compounding has been actively narrowing — meaning the regulatory ground compounded GLP-1s stand on has shifted more than once and is not a stable, permanent category the way an FDA-approved generic would be.

Compounded Doesn't Mean Identical

A compounding pharmacy is legally permitted to alter the formulation — this is, in fact, part of what distinguishes legitimate compounding from simply copying a drug: compounders can adjust dosage form, add other ingredients (as seen in some 'semaglutide plus B12' or combination products), or use salt forms like semaglutide sodium or semaglutide acetate rather than the exact salt form used in the FDA-approved product. These variations haven't gone through the same large-scale clinical trials as the approved drug, so their absorption, potency consistency, and side-effect profile aren't guaranteed to match the branded product even when the active ingredient is nominally the same molecule.

Where the Real Risk Shows Up

FDA adverse-event reports and public warnings have flagged two recurring problems with compounded GLP-1 products: dosing errors from inconsistent concentration between vials or pens (patients drawing up the wrong volume for their intended dose), and outright counterfeit or illegitimate product entering the supply chain through non-licensed sellers posing as compounding pharmacies. Legitimate state-licensed compounding pharmacies operating under a valid prescription are a meaningfully different risk category than the unregulated online sellers that have proliferated alongside GLP-1 demand — the two get conflated in public discussion, but the oversight, sourcing, and quality control involved are not comparable.

Practical Signs of a Legitimate Source

• Requires an actual prescription from a licensed prescriber, not just a questionnaire with no clinical oversight
• Dispensed by a pharmacy with a verifiable state license, not a research-chemical or 'not for human consumption' seller
• Clear, consistent labeling of concentration and volume per dose
• Willing to answer direct questions about sourcing and formulation

Practical Takeaway

Compounded GLP-1s are a real, legally distinct category built on a narrowing shortage exception, not simply cheaper generics of the branded drugs. The formulation differences are legally permitted but not necessarily clinically validated at the same scale, and the biggest documented real-world risks — dosing inconsistency and counterfeit product — concentrate specifically around unlicensed sellers rather than legitimate, prescription-based compounding pharmacies. Sourcing matters as much as the molecule itself.